BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 9761119)

  • 21. Immunofluorometrically determined p53 accumulation as a prognostic indicator in Italian breast cancer patients.
    Levesque MA; Katsaros D; Yu H; Giai M; Genta F; Roagna R; Ponzone R; Massobrio M; Sismondi P; Diamandis EP
    Int J Cancer; 1998 Apr; 79(2):147-52. PubMed ID: 9583729
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Peroxiredoxin 4 as an independent prognostic marker for survival in patients with early-stage lung squamous cell carcinoma.
    Hwang JA; Song JS; Yu DY; Kim HR; Park HJ; Park YS; Kim WS; Choi CM
    Int J Clin Exp Pathol; 2015; 8(6):6627-35. PubMed ID: 26261544
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High frequency of coexpression of maspin with p63 and p53 in squamous cell carcinoma but not in adenocarcinoma of the lung.
    Choy B; Findeis-Hosey JJ; Li F; McMahon LA; Yang Q; Xu H
    Int J Clin Exp Pathol; 2013; 6(11):2542-7. PubMed ID: 24228118
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enzyme-linked immunoabsorbent assay-detected p53 protein accumulation: a prognostic factor in a large breast cancer cohort.
    Levesque MA; Yu H; Clark GM; Diamandis EP
    J Clin Oncol; 1998 Aug; 16(8):2641-50. PubMed ID: 9704714
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluations of p53 immunoreactivity, nucleolar organizer regions, and proliferating cell nuclear antigen in non-small cell lung carcinoma.
    Oyama T; Osaki T; Nose N; Ichiki Y; Inoue M; Imoto H; Yoshimatsu T; Kodate M; Uramoto H; Mizoue T; Yano K; Yasumoto K
    Anticancer Res; 2000; 20(1B):505-10. PubMed ID: 10769714
    [TBL] [Abstract][Full Text] [Related]  

  • 26. p53 and bcl-2 protein expression in non-small-cell lung carcinoma.
    Athanassiadou P; Dosios T; Petrakakou E; Liossi A; Zerva C; Athanassiades P
    Diagn Cytopathol; 1998 Oct; 19(4):255-9. PubMed ID: 9784987
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination.
    Yu H; Levesque MA; Clark GM; Diamandis EP
    Br J Cancer; 1999 Oct; 81(3):490-5. PubMed ID: 10507775
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Programmed Death Cell Ligand 1 (PD-L1) Is Associated With Survival in Stage I Non-Small Cell Lung Cancer.
    Sepesi B; Cuentas EP; Canales JR; Behrens C; Correa AM; Vaporciyan A; Weissferdt A; Kalhor N; Moran C; Swisher S; Wistuba I
    Semin Thorac Cardiovasc Surg; 2017 Autumn; 29(3):408-415. PubMed ID: 29195578
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The 3' UTR IGF2R-A2/B2 variant is associated with increased tumor growth and advanced stages in non-small cell lung cancer.
    Kotsinas A; Evangelou K; Sideridou M; Kotzamanis G; Constantinides C; Zavras AI; Douglass CW; Papavassiliou AG; Gorgoulis VG
    Cancer Lett; 2008 Feb; 259(2):177-85. PubMed ID: 18037232
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The relationship between microvessel count and the expression of vascular endothelial growth factor, p53, and K-ras in non-small cell lung cancer.
    Kang YH; Kim KS; Yu YK; Lim SC; Kim YC; Park KO
    J Korean Med Sci; 2001 Aug; 16(4):417-23. PubMed ID: 11511786
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epidermal growth factor receptor expression correlates with poor prognosis in non-small cell lung cancer patients with p53 overexpression.
    Ohsaki Y; Tanno S; Fujita Y; Toyoshima E; Fujiuchi S; Nishigaki Y; Ishida S; Nagase A; Miyokawa N; Hirata S; Kikuchi K
    Oncol Rep; 2000; 7(3):603-7. PubMed ID: 10767376
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic role of serum p53 antibodies in lung cancer.
    Mattioni M; Soddu S; Prodosmo A; Visca P; Conti S; Alessandrini G; Facciolo F; Strigari L
    BMC Cancer; 2015 Mar; 15():148. PubMed ID: 25884692
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical value of p53, c-erbB-2, CEA and CA125 regarding relapse, metastasis and death in resectable non-small cell lung cancer.
    Pollán M; Varela G; Torres A; de la Torre M; Ludeña MD; Ortega MD; Pac J; Freixenet J; Gómez G; Sebastián F; Díez M; Arrabal R; Canalís E; García-Tirado J; Arnedillo A; Rivas JJ; Minguella J; Gómez A; García M; Aragonés N; Pérez-Gómez B; López-Abente G; González-Sarmiento R; Rojas JM
    Int J Cancer; 2003 Dec; 107(5):781-90. PubMed ID: 14566828
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic significance of p53 and ras p21 expression in nonsmall cell lung cancer.
    Fujino M; Dosaka-Akita H; Harada M; Hiroumi H; Kinoshita I; Akie K; Kawakami Y
    Cancer; 1995 Dec; 76(12):2457-63. PubMed ID: 8625071
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MCM2 is an independent predictor of survival in patients with non-small-cell lung cancer.
    Ramnath N; Hernandez FJ; Tan DF; Huberman JA; Natarajan N; Beck AF; Hyland A; Todorov IT; Brooks JS; Bepler G
    J Clin Oncol; 2001 Nov; 19(22):4259-66. PubMed ID: 11709570
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evidence for a dose-response effect between p53 (but not p21WAF1/Cip1) protein concentrations, survival, and responsiveness in patients with epithelial ovarian cancer treated with platinum-based chemotherapy.
    Levesque MA; Katsaros D; Massobrio M; Genta F; Yu H; Richiardi G; Fracchioli S; Durando A; Arisio R; Diamandis EP
    Clin Cancer Res; 2000 Aug; 6(8):3260-70. PubMed ID: 10955812
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predictive value of expression of p16INK4A, retinoblastoma and p53 proteins for the prognosis of non-small-cell lung cancers.
    Hommura F; Dosaka-Akita H; Kinoshita I; Mishina T; Hiroumi H; Ogura S; Katoh H; Kawakami Y
    Br J Cancer; 1999 Oct; 81(4):696-701. PubMed ID: 10574258
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [p53 alterations in human lung cancer and their correlation with clinicopathological features and prognosis].
    Zhang J; Zheng J; Fang W
    Zhonghua Bing Li Xue Za Zhi; 1998 Aug; 27(4):286-9. PubMed ID: 11244999
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cluster analysis of p-glycoprotein, c-erb-B2 and P53 in relation to tumor histology strongly indicates prognosis in patients with operable non-small cell lung cancer.
    Bozcuk H; Gumus A; Ozbilim G; Sarper A; Kucukosmanoglu I; Ozbudak IH; Artac M; Ozdogan M; Samur M; Kaya A; Savas B
    Med Sci Monit; 2005 Jun; 11(6):HY11-20. PubMed ID: 15917726
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic prediction of the immunohistochemical expression of p53 and p16 in resected non-small cell lung cancer.
    Cheng YL; Lee SC; Harn HJ; Chen CJ; Chang YC; Chen JC; Yu CP
    Eur J Cardiothorac Surg; 2003 Feb; 23(2):221-8. PubMed ID: 12559346
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.